Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.

European urology oncology - 1 Feb 2026

Robbrecht Debbie G J, Salhi Youssra, Martens John W M, Aarts Maureen J B, Hamberg Paul, van der Heijden Michiel S, Voortman Jens, Mehra Niven, Westgeest Hans M, de Wit Ronald, Debets Reno, Boormans Joost L, Nakauma-González J Alberto

Abstract excerpt

The current options and recent developments in the field of systemic therapy for advanced urothelial cancer (UC) patients urge the need for selection criteria to identify the most optimal therapeutic option for individual patients. The molecular makeup of tumors, including molecular subtype, tumor microenvironment composition, and gene mutations, fusions, and amplifications, has previously been correlated with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Cell Adhesion Molecules

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Nectins

Share to Neoplasm Metastasis

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 40300922
DOI: 10.1016/j.euo.2025.04.007

Genes

FGFR2
NECTIN4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.PMID 40300922Read ↗

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity Read ↗

Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinomaSemantic proximity Read ↗

Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapySemantic proximity Read ↗

Similar genetic profile in early and late stage urothelial tract cancer.Semantic proximity Read ↗

The genomic and transcriptomic landscape of metastastic urothelial cancer.Semantic proximity Read ↗

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerSemantic proximity Read ↗

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortSemantic proximity Read ↗

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial CarcinomaSemantic proximity Read ↗

T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancerSemantic proximity Read ↗

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read ↗

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Semantic proximity Read ↗

Biomarker-Oriented Therapy in Bladder and Renal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.